Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simpler stomach bug treatment on the horizon?

NCT ID NCT06977841

Disease control Sponsor: Zhongshan Hospital (Xiamen), Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested different combinations of the acid-blocker tegoprazan with antibiotics to treat H. pylori, a common stomach infection. 640 adults who had never been treated before received one of several drug regimens for 14 days. The goal was to see which combination worked best with the fewest side effects, aiming to simplify treatment and reduce antibiotic resistance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tegoprazan (a stomach acid blocker) combined with antibiotics (amoxicillin or tetracycline)
What this could lead to
If successful, this could lead to simpler, better-tolerated treatment regimens for H. pylori infection, reducing side effects and antibiotic resistance.
What could go wrong
This is a completed trial, but results are not yet published. The new drug combinations may not be more effective than current standard treatments, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

640 people

The number who actually took part.

Started

Jun 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age from 18 to 70 years; 2. H. pylori infection diagnosed by ¹³C-urea breath test or rapid urease test during endoscopy; 3. The patient infected with Helicobacter pylori has never undergone eradication therapy. Exclusion Criteria: 1. Patients with a definite history of allergy to the study drugs (tegoprazan, amoxicillin, tetracycline, or bismuth potassium citrate); 2. Those who have used any proton pump inhibitors, potassium-competitive acid blockers, antibiotics, bismuth agents, or H₂ receptor antagonists within 4 weeks prior to enrollment; 3. Those with concomitant severe cardiovascular, pulmonary, hepatic, renal, or other systemic diseases (e.g., New York Heart Association functional class III-IV, chronic kidney disease stage 3 or higher, Child-Pugh class B or higher cirrhosis); 4. Those requiring long-term use of systemic corticosteroids, anticoagulants, or antiplatelet agents (excluding aspirin \<100 mg daily); 5. Pregnant or breastfeeding women; 6. Those with a history of drug abuse or alcohol dependence within the past 1 year; 7. Those with a current or prior history of malignancy at any site; 8. Those with active gastrointestinal bleeding or unexplained iron deficiency anemia; 9. Those with severe psychiatric disorders that may compromise compliance with the study; 10. Those who have participated in other interventional clinical trials within 3 months prior to enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adverse reaction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adverse reaction Helicobacter pylori eradication High-dose dual therapy

Contacts and locations

Locations

  • Zhongshan Hospital (Xiamen), Fudan University

    Xiamen, Fujian, 361015, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.